Review Article Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan Lee-Jen Chen a , Cheng-Kuo Cheng b,c,d , Ling Yeung e,f , Chang-Hao Yang g , Shih-Jen Chen h,i, *, Taiwan PCV consensus group a Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan b Department of Ophthalmology, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan c Department of Ophthalmology, School of Medicine, National Taiwan University, Taipei, Taiwan d Department of Ophthalmology, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan e Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan f College of Medicine, Chang Gung University, Taoyuan, Taiwan g Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan h Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan i Department of Ophthalmology, School of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan Received 29 November 2018; received in revised form 8 April 2019; accepted 18 April 2019 KEYWORDS Choroidal neovascularization; PCV; Photodynamic therapy; Vascular endothelial growth factors; Wet age-related macular degeneration Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for pa- tients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited re- sources for the patients, an expert meeting was held to provide updated Taiwan consensus rec- ommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve health- care quality and reduce burden of disease and treatment for patients with PCV. * Corresponding author. No. 201, Sec. 2, Shih-Pai Road, Taipei, 11217, Taiwan. E-mail address: sjchen@vghtpe.gov.tw (S.-J. Chen). + MODEL Please cite this article as: Chen L-J et al., Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan, Journal of the Formosan Medical Association, https://doi.org/10.1016/j.jfma.2019.04.012 https://doi.org/10.1016/j.jfma.2019.04.012 0929-6646/Copyright ª 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Available online at www.sciencedirect.com ScienceDirect journal homepage: www.jfma-online.com Journal of the Formosan Medical Association xxx (xxxx) xxx